Sfoglia per Autore
Listening Social Media for Pharmacovigilance Objectives: Which Usefulness?
2019-01-01 Convertino, I; Leonardi, L; Tuccori, M; Ferraro, S; Blandizzi, C
The Economic Impact of the Introduction of Infliximab-Biosimilar: Preliminary Results from a Study on Rheumatologic Patients in Tuscany, Italy
2019-01-01 Lorenzoni, V; Trieste, L; Mosca, M; Convertino, I; Tuccori, M; Lucenteforte, E; Ferraro, S; Leonardi, L; Roberto, G; Luciano, N; Blandizzi, C; Gini, R; Turchetti, G
Anticoagulant Therapy and Risk of Bleeding in Patients with Atrial Fibrillation of Four Italian Regions: The TYRION Study
2019-01-01 Convertino, I; Leonardi, L; Tuccori, M; Ferraro, S; Salvadori, S; Franchini, M; De Carlo, I; Kirchmayer, U; Corona, T; Riengler, S; Menditto, E; Parrilli, M; Rossi, M; Orlando, V; Pieroni, S; Vannacci, A
Anti-tumor Necrosis Factor Drugs and Risk of Lymphoma in Patients with Inflammatory Bowel Disease
2019-01-01 Blandizzi, C; Tuccori, M; Ferraro, S; Leonardi, L; Convertino, I
Switching from infliximab-originator to infliximab-biosimilar in rheumatologic patients: The clinical impact in Tuscan Region, Italy
2019-01-01 Convertino, I; Tuccori, M; Lucenteforte, E; Mosca, M; Turchetti, G; Lorenzoni, V; Trieste, L; Ferraro, S; Leonardi, L; Roberto, G; Luciano, N; Blandizzi, C; Gini, R
Italian Emergency Department Visits and Hospitalizations for Outpatients’ Adverse Drug Events: 12-Year Active Pharmacovigilance Surveillance (The MEREAFaPS Study)
2020-01-01 Lombardi, Niccolò; Crescioli, Giada; Bettiol, Alessandra; Tuccori, Marco; Capuano, Annalisa; Bonaiuti, Roberto; Mugelli, Alessandro; Venegoni, Mauro; Danilo Vighi, Giuseppe; Vannacci, Alfredo; Convertino, Irma
Exploring pharmacological approaches for managing cytokine storm associated with pneumonia and acute respiratory distress syndrome in COVID-19 patients
2020-01-01 Convertino, I.; Tuccori, M.; Ferraro, S.; Valdiserra, G.; Cappello, E.; Focosi, D.; Blandizzi, C.
Risk of hospitalisation associated with benzodiazepines and z-drugs in Italy: a nationwide multicentre study in emergency departments
2020-01-01 Lombardi, N.; Bettiol, A.; Crescioli, G.; Ravaldi, C.; Bonaiuti, R.; Venegoni, M.; Vighi, G. D.; Mugelli, A.; Mannaioni, G.; Vannacci, A.; Aiezza, M. L.; Bettoni, D.; Blandizzi, C.; Borsi, V.; Capuano, A.; Cecchi, E.; Convertino, I.; Lungo, M. D.; Mauro, C. D.; Farina, G.; Ferraro, S.; Fucile, A.; Galfrascoli, E.; Geninatti, E.; Giovannetti, L.; Leonardi, L.; Liccardo, R.; Marra, A.; Marrazzo, E.; Monina, G.; Pagani, S.; Parrilli, M.; Rafaniello, C.; Rossi, F.; Rossi, M.; Rostan, S.; Ruocco, M.; Sironi, M.; Spada, G.; Sportiello, L.; Tuccori, M.; Vighi, G. V.
The Impact of the COVID-19 “Infodemic” on Drug-Utilization Behaviors: Implications for Pharmacovigilance
2020-01-01 Tuccori, M.; Convertino, I.; Ferraro, S.; Cappello, E.; Valdiserra, G.; Focosi, D.; Blandizzi, C.
Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline
2020-01-01 Tuccori, M.; Ferraro, S.; Convertino, I.; Cappello, E.; Valdiserra, G.; Blandizzi, C.; Maggi, F.; Focosi, D.
Authors’ response: Inhibiting IL-6 in COVID-19: we are not sure that sgp130(fc) can affect only the trans-signaling receptor pathway of IL-6
2020-01-01 Convertino, Irma; Tuccori, Marco; Blandizzi, Corrado
Trajectories of use of biologic disease modifying antirheumatic drugs in rheumatoid arthritis: A cohort study of Tuscan patients, Italy
2020-01-01 Convertino, I; Giometto, S; Gini, R; Cazzato, M; Valdiserra, G; Cappello, E; Ferraro, S; Fornili, M; Turchetti, G; Lorenzoni, V; Trieste, L; Mosca, M; Blandizzi, C; Tuccori, M; Lucenteforte, E
Time to biologic treatment and to total colectomy associated with diagnostic delay in ulcerative colitis: Analysis of an Italian regional administrative healthcare database
2020-01-01 Ferraro, S; Bartolini, C; Bertani, L; Convertino, I; Lucenteforte, E; Costa, F; Valdiserra, G; Cappello, E; Blandizzi, C; Gini, R; Tuccori, M
Oral Presentation: Accesses to Emergency Department and Hospitalizations in New Users of Biologic Therapies for Ulcerative Colitis in Tuscany: The MICHELANGELO Study
2021-01-01 Valdiserra, G.; Tillati, S.; Lorenzoni, V.; Gini, R.; Turchetti, G.; Giometto, S.; Bartolini, C.; Paoletti, O.; Convertino, I.; Ferraro, S.; Cappello, E.; Fornai, M.; Lucenteforte, E.; Tuccori, M.
Direct health care costs among patients with rheumatoid arthritis before and after the initiation of treatment with JAKi in Tuscany: The LEONARDO study
2021-01-01 Lorenzoni, V; Tuccori, M; Gini, R; Fini, E; Giometto, S; Bartolini, C; Paoletti, O; Convertino, I; Ferraro, S; Cappello, E; Valdiserra, G; Blandizzi, C; Lucenteforte, E; Turchetti, G
Validation test for algorithms to identify rheumatoid arthritis patients in the Tuscan healthcare administrative databases
2021-01-01 Convertino, I; Cazzato, M; Giometto, S; Gini, R; Lucenteforte, E; Valdiserra, G; Cappello, E; Ferraro, S; Tillati, S; Fornili, M; Bartolini, C; Paoletti, O; Lorenzoni, V; Trieste, L; Filippi, M; Turchetti, G; Cristofano, M; Blandizzi, C; Mosca, M; Tuccori, M
Diagnostic delay, effectiveness and safety outcomes in a real-world cohort of patients with Crohn's disease: Data from administrative databases in Tuscany, Italy
2021-01-01 Ferraro, S; Bartolini, C; Convertino, I; Bertani, L; Giometto, S; Cappello, E; Valdiserra, G; Tillati, S; Blandizzi, C; Lucenteforte, E; Costa, F; Gini, R; Tuccori, M
Adherence to mesalazine and identification of patients with ulcerative colitis in healthcare administrative databases of Tuscany (Italy)
2021-01-01 Bartolini, C; Ferraro, S; Convertino, I; Bertani, L; Giometto, S; Costa, F; Blandizzi, C; Lucenteforte, E; Gini, R; Tuccori, M
Utilization patterns and healthcare accesses of JAKi used in rheumatoid arthritis patients in Tuscany: The LEONARDO study
2021-01-01 Tuccori, M; Lorenzoni, V; Gini, R; Turchetti, G; Fini, E; Giometto, S; Bartolini, C; Paoletti, O; Convertino, I; Ferraro, S; Cappello, E; Valdiserra, G; Blandizzi, C; Lucenteforte, E
Analysis of fatal adverse drug events recorded in several Italian emergency departments (the MEREAFaPS study)
2021-01-01 Pagani, S.; Lombardi, N.; Crescioli, G.; Vighi, G. V.; Spada, G.; Romoli, I.; Andreetta, P.; Capuano, A.; Marrazzo, E.; Marra, A.; Leoni, O.; Vannacci, A.; Venegoni, M.; Vighi, G. D.; Bettoni, D.; Blandizzi, C.; Bonaiuti, R.; Borsi, V.; Cecchi, E.; Convertino, I.; Del Lungo, M.; Di Mauro, C.; Farina, G.; Ferraro, S.; Fucile, A.; Galfrascoli, E.; Geninatti, E.; Giovannetti, L.; Leonardi, L.; Liccardo, R.; Monina, G.; Mugelli, A.; Pagani, S.; Parrilli, M.; Rafaniello, C.; Rossi, F.; Rostan, S.; Ruocco, M.; Sironi, M.; Sportiello, L.; Tuccori, M.
Titolo | Data di pubblicazione | Autore(i) | File |
---|---|---|---|
Listening Social Media for Pharmacovigilance Objectives: Which Usefulness? | 1-gen-2019 | Convertino, I; Leonardi, L; Tuccori, M; Ferraro, S; Blandizzi, C | |
The Economic Impact of the Introduction of Infliximab-Biosimilar: Preliminary Results from a Study on Rheumatologic Patients in Tuscany, Italy | 1-gen-2019 | Lorenzoni, V; Trieste, L; Mosca, M; Convertino, I; Tuccori, M; Lucenteforte, E; Ferraro, S; Leonardi, L; Roberto, G; Luciano, N; Blandizzi, C; Gini, R; Turchetti, G | |
Anticoagulant Therapy and Risk of Bleeding in Patients with Atrial Fibrillation of Four Italian Regions: The TYRION Study | 1-gen-2019 | Convertino, I; Leonardi, L; Tuccori, M; Ferraro, S; Salvadori, S; Franchini, M; De Carlo, I; Kirchmayer, U; Corona, T; Riengler, S; Menditto, E; Parrilli, M; Rossi, M; Orlando, V; Pieroni, S; Vannacci, A | |
Anti-tumor Necrosis Factor Drugs and Risk of Lymphoma in Patients with Inflammatory Bowel Disease | 1-gen-2019 | Blandizzi, C; Tuccori, M; Ferraro, S; Leonardi, L; Convertino, I | |
Switching from infliximab-originator to infliximab-biosimilar in rheumatologic patients: The clinical impact in Tuscan Region, Italy | 1-gen-2019 | Convertino, I; Tuccori, M; Lucenteforte, E; Mosca, M; Turchetti, G; Lorenzoni, V; Trieste, L; Ferraro, S; Leonardi, L; Roberto, G; Luciano, N; Blandizzi, C; Gini, R | |
Italian Emergency Department Visits and Hospitalizations for Outpatients’ Adverse Drug Events: 12-Year Active Pharmacovigilance Surveillance (The MEREAFaPS Study) | 1-gen-2020 | Lombardi, Niccolò; Crescioli, Giada; Bettiol, Alessandra; Tuccori, Marco; Capuano, Annalisa; Bonaiuti, Roberto; Mugelli, Alessandro; Venegoni, Mauro; Danilo Vighi, Giuseppe; Vannacci, Alfredo; Convertino, Irma | |
Exploring pharmacological approaches for managing cytokine storm associated with pneumonia and acute respiratory distress syndrome in COVID-19 patients | 1-gen-2020 | Convertino, I.; Tuccori, M.; Ferraro, S.; Valdiserra, G.; Cappello, E.; Focosi, D.; Blandizzi, C. | |
Risk of hospitalisation associated with benzodiazepines and z-drugs in Italy: a nationwide multicentre study in emergency departments | 1-gen-2020 | Lombardi, N.; Bettiol, A.; Crescioli, G.; Ravaldi, C.; Bonaiuti, R.; Venegoni, M.; Vighi, G. D.; Mugelli, A.; Mannaioni, G.; Vannacci, A.; Aiezza, M. L.; Bettoni, D.; Blandizzi, C.; Borsi, V.; Capuano, A.; Cecchi, E.; Convertino, I.; Lungo, M. D.; Mauro, C. D.; Farina, G.; Ferraro, S.; Fucile, A.; Galfrascoli, E.; Geninatti, E.; Giovannetti, L.; Leonardi, L.; Liccardo, R.; Marra, A.; Marrazzo, E.; Monina, G.; Pagani, S.; Parrilli, M.; Rafaniello, C.; Rossi, F.; Rossi, M.; Rostan, S.; Ruocco, M.; Sironi, M.; Spada, G.; Sportiello, L.; Tuccori, M.; Vighi, G. V. | |
The Impact of the COVID-19 “Infodemic” on Drug-Utilization Behaviors: Implications for Pharmacovigilance | 1-gen-2020 | Tuccori, M.; Convertino, I.; Ferraro, S.; Cappello, E.; Valdiserra, G.; Focosi, D.; Blandizzi, C. | |
Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline | 1-gen-2020 | Tuccori, M.; Ferraro, S.; Convertino, I.; Cappello, E.; Valdiserra, G.; Blandizzi, C.; Maggi, F.; Focosi, D. | |
Authors’ response: Inhibiting IL-6 in COVID-19: we are not sure that sgp130(fc) can affect only the trans-signaling receptor pathway of IL-6 | 1-gen-2020 | Convertino, Irma; Tuccori, Marco; Blandizzi, Corrado | |
Trajectories of use of biologic disease modifying antirheumatic drugs in rheumatoid arthritis: A cohort study of Tuscan patients, Italy | 1-gen-2020 | Convertino, I; Giometto, S; Gini, R; Cazzato, M; Valdiserra, G; Cappello, E; Ferraro, S; Fornili, M; Turchetti, G; Lorenzoni, V; Trieste, L; Mosca, M; Blandizzi, C; Tuccori, M; Lucenteforte, E | |
Time to biologic treatment and to total colectomy associated with diagnostic delay in ulcerative colitis: Analysis of an Italian regional administrative healthcare database | 1-gen-2020 | Ferraro, S; Bartolini, C; Bertani, L; Convertino, I; Lucenteforte, E; Costa, F; Valdiserra, G; Cappello, E; Blandizzi, C; Gini, R; Tuccori, M | |
Oral Presentation: Accesses to Emergency Department and Hospitalizations in New Users of Biologic Therapies for Ulcerative Colitis in Tuscany: The MICHELANGELO Study | 1-gen-2021 | Valdiserra, G.; Tillati, S.; Lorenzoni, V.; Gini, R.; Turchetti, G.; Giometto, S.; Bartolini, C.; Paoletti, O.; Convertino, I.; Ferraro, S.; Cappello, E.; Fornai, M.; Lucenteforte, E.; Tuccori, M. | |
Direct health care costs among patients with rheumatoid arthritis before and after the initiation of treatment with JAKi in Tuscany: The LEONARDO study | 1-gen-2021 | Lorenzoni, V; Tuccori, M; Gini, R; Fini, E; Giometto, S; Bartolini, C; Paoletti, O; Convertino, I; Ferraro, S; Cappello, E; Valdiserra, G; Blandizzi, C; Lucenteforte, E; Turchetti, G | |
Validation test for algorithms to identify rheumatoid arthritis patients in the Tuscan healthcare administrative databases | 1-gen-2021 | Convertino, I; Cazzato, M; Giometto, S; Gini, R; Lucenteforte, E; Valdiserra, G; Cappello, E; Ferraro, S; Tillati, S; Fornili, M; Bartolini, C; Paoletti, O; Lorenzoni, V; Trieste, L; Filippi, M; Turchetti, G; Cristofano, M; Blandizzi, C; Mosca, M; Tuccori, M | |
Diagnostic delay, effectiveness and safety outcomes in a real-world cohort of patients with Crohn's disease: Data from administrative databases in Tuscany, Italy | 1-gen-2021 | Ferraro, S; Bartolini, C; Convertino, I; Bertani, L; Giometto, S; Cappello, E; Valdiserra, G; Tillati, S; Blandizzi, C; Lucenteforte, E; Costa, F; Gini, R; Tuccori, M | |
Adherence to mesalazine and identification of patients with ulcerative colitis in healthcare administrative databases of Tuscany (Italy) | 1-gen-2021 | Bartolini, C; Ferraro, S; Convertino, I; Bertani, L; Giometto, S; Costa, F; Blandizzi, C; Lucenteforte, E; Gini, R; Tuccori, M | |
Utilization patterns and healthcare accesses of JAKi used in rheumatoid arthritis patients in Tuscany: The LEONARDO study | 1-gen-2021 | Tuccori, M; Lorenzoni, V; Gini, R; Turchetti, G; Fini, E; Giometto, S; Bartolini, C; Paoletti, O; Convertino, I; Ferraro, S; Cappello, E; Valdiserra, G; Blandizzi, C; Lucenteforte, E | |
Analysis of fatal adverse drug events recorded in several Italian emergency departments (the MEREAFaPS study) | 1-gen-2021 | Pagani, S.; Lombardi, N.; Crescioli, G.; Vighi, G. V.; Spada, G.; Romoli, I.; Andreetta, P.; Capuano, A.; Marrazzo, E.; Marra, A.; Leoni, O.; Vannacci, A.; Venegoni, M.; Vighi, G. D.; Bettoni, D.; Blandizzi, C.; Bonaiuti, R.; Borsi, V.; Cecchi, E.; Convertino, I.; Del Lungo, M.; Di Mauro, C.; Farina, G.; Ferraro, S.; Fucile, A.; Galfrascoli, E.; Geninatti, E.; Giovannetti, L.; Leonardi, L.; Liccardo, R.; Monina, G.; Mugelli, A.; Pagani, S.; Parrilli, M.; Rafaniello, C.; Rossi, F.; Rostan, S.; Ruocco, M.; Sironi, M.; Sportiello, L.; Tuccori, M. |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile